ST008 Male Androgenetic Alopecia: A New Treatment Paradigm

    Rodney P.R. Dawber
    Image of study
    TLDR New treatment improves male hair loss.
    The document contains summaries of several satellite symposia on various dermatological topics. One of the symposia discusses a new treatment paradigm for male androgenetic alopecia, which affects approximately 50% of the male population by age 40. The symposium covers the science of hair growth cycles, the effect of androgens on hair growth cycles, and the role of the enzyme 5α-reductase and its end product, dihydrotestosterone (DHT), in the pathogenesis of androgenetic alopecia. The symposium also presents the results of clinical trials evaluating finasteride, an inhibitor of the Type 11 isoform of 5α-reductase, for the treatment of men with androgenetic alopecia.
    Discuss this study in the Community →

    Related

    19 / 19 results